Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Adicet Bio Inc (ACET)

Adicet Bio Inc (ACET)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference Business Wire - Thu May 14, 3:00PM CDT

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen...

ACET : 8.30 (+5.20%)
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates Business Wire - Wed May 13, 3:01PM CDT

Clinical update anticipated in mid-2026 for Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001) with at least 20 lupus nephritis (LN) and systemic lupus erythematosus...

ACET : 8.30 (+5.20%)
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress Business Wire - Thu Mar 12, 3:00PM CDT

Strong enrollment momentum in Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001); clinical update expected in 1H/2026 with an additional update in 2H/2026 ...

ACET : 8.30 (+5.20%)
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Business Wire - Fri Jan 30, 6:00AM CST

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen...

ACET : 8.30 (+5.20%)
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones Business Wire - Wed Jan 7, 6:00AM CST

Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients with prulacabtagene leucel (prula-cel, formerly...

ACET : 8.30 (+5.20%)
Adicet Bio Announces Reverse Stock Split Business Wire - Fri Dec 26, 2025

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board...

ACET : 8.30 (+5.20%)
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Nov 28, 2025

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted...

ACET : 8.30 (+5.20%)
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates Business Wire - Wed Nov 5, 2025

Announced positive preliminary safety and efficacy data from Phase 1 clinical trial of ADI-001 in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE); data highlighted rapid and sustained...

ACET : 8.30 (+5.20%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Oct 31, 2025

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted...

ACET : 8.30 (+5.20%)
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference Business Wire - Tue Oct 28, 2025

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen...

ACET : 8.30 (+5.20%)

Barchart Exclusives

Can November Soybeans Challenge Contract Highs? Strong Crush Demand and Seasonal Strength Say It's Possible Barchart - Sat May 23, 3:37PM CDT
November soybeans may be setting up one of the better seasonal opportunities in ag markets right now. Record crush demand, bullish technicals, and a weather market season are all lining up at the same time.MRCI research also shows Nov beans closed higher in this seasonal window 12 of the past 15 years, with 8 of those years seeing no daily closing drawdowns.That kind of historical consistency gets traders' attention! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.